Hybrid Enzyme‐Polymeric Capsules/Mesoporous Silica Nanodevice for In Situ Cytotoxic Agent Generation
Source abstract
Abstract
A novel nanocarrier based on functionalized mesoporous silica nanoparticles able to transport a non‐toxic pro‐drug and the enzyme responsible for its activation is presented. This nanodevice is able to generate in situ cytotoxic species once accumulated in the tumoral cell. Enzymes are sensitive macromolecules which can suffer denaturalization in biological media due to the presence of proteases or other aggressive agents. Moreover, the direct attachment of enzymes to the silica surface can reduce their activity by conformational changes or active site blockage. For these reasons, in order to create a robust system able to work in living organisms, the enzymes are previously coated with a protective polymeric shell which allows the attachment on the silica surface preserving their activity. The efficacy of this hybrid nanodevice for antitumoral purposes is tested against several human tumoral cells as neuroblastoma and leukemia showing significant efficacy. It converts this device in a promising candidate for further in vivo studies for oncology therapy.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Enzyme Catalysis and Immobilization · Mesoporous Materials and Catalysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Centro de Investigación Biomédica en Red de Bioingeniería, Biomaterialesy Nanomedicina (CIBER‐BBN), Dpto. Química Inorgánica y Bioinorgánica UCM, Instituto de Investigación Sanitaria Hospital, 12 de Octubre i+12. CEI Campus Moncloa, UCM‐UPM Plaza Ramón y Cajal s/n 28040 Madrid Spain
Dpto. de Química Inorgánica Facultad de Químicas UCM, Madrid Spain
Dpto. de Hematología y Oncología Pediátricas del Hospital Infantil Universitario Niño Jesús Madrid Spain
References (41)
Show source-provided references
1. 10.1016/j.addr.2012.09.00610.1016/j.addr.2012.09.006 ↗
2. 10.1038/nrc318010.1038/nrc3180 ↗
3. 10.1016/j.bmc.2009.02.04310.1016/j.bmc.2009.02.043 ↗
4. 10.1016/j.addr.2012.10.00210.1016/j.addr.2012.10.002 ↗
5. 10.1038/nrclinonc.2010.13910.1038/nrclinonc.2010.139 ↗
6. 10.1021/nn102324e10.1021/nn102324e ↗
7. 10.1016/j.ejpb.2011.08.00410.1016/j.ejpb.2011.08.004 ↗
8. 10.1021/ar200027710.1021/ar2000277 ↗
9. 10.1039/C2BM00085G10.1039/C2BM00085G ↗
10. 10.1002/adma.20110476310.1002/adma.201104763 ↗
11. Vallet‐Regí M. · 2013
12. 10.1002/smll.20110159310.1002/smll.201101593 ↗
13. 10.1002/adma.20110158610.1002/adma.201101586 ↗
14. 10.1166/jbt.2011.100610.1166/jbt.2011.1006 ↗
15. 10.1039/c1cs15246g10.1039/c1cs15246g ↗
16. 10.1016/j.addr.2012.07.01810.1016/j.addr.2012.07.018 ↗
17. 10.1002/smll.20100053810.1002/smll.201000538 ↗
18. 10.1021/nn103077k10.1021/nn103077k ↗
19. 10.1021/cm203000u10.1021/cm203000u ↗
20. 10.1021/nn102922910.1021/nn1029229 ↗
21. 10.1016/j.addr.2012.09.03810.1016/j.addr.2012.09.038 ↗
22. 10.1002/anie.20120641610.1002/anie.201206416 ↗
23. 10.1002/9783527633166.ch1210.1002/9783527633166.ch12 ↗
24. 10.1038/nrd246810.1038/nrd2468 ↗
25. 10.1124/pr.56.1.310.1124/pr.56.1.3 ↗
26. 10.1016/S0898-6568(03)00091-310.1016/S0898-6568(03)00091-3 ↗
27. 10.1016/j.toxlet.2003.12.06710.1016/j.toxlet.2003.12.067 ↗
28. 10.1002/cbf.138310.1002/cbf.1383 ↗
29. 10.1002/cbf.152810.1002/cbf.1528 ↗
30. 10.1016/j.enzmictec.2007.01.01810.1016/j.enzmictec.2007.01.018 ↗
31. 10.1016/0167-4838(95)00133-F10.1016/0167-4838(95)00133-F ↗
32. 10.1002/anie.20050307510.1002/anie.200503075 ↗
33. 10.1002/smll.20090000510.1002/smll.200900005 ↗
34. 10.1021/ja071978010.1021/ja0719780 ↗
35. 10.1016/S0168-3659(01)00486-210.1016/S0168-3659(01)00486-2 ↗
36. Greco O. · Mol. Cancer Ther. · 2001 · 1 · 151
37. 10.1021/bc970116t10.1021/bc970116t ↗
38. 10.1038/nnano.2012.26410.1038/nnano.2012.264 ↗
39. 10.1038/nnano.2009.34110.1038/nnano.2009.341 ↗
40. 10.1177/00045632840210051610.1177/000456328402100516 ↗
41. 10.1016/S0006-2952(00)00498-610.1016/S0006-2952(00)00498-6 ↗